MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Clinical Outcomes of Deep Brain Stimulation in Malaysian Children with Pharmacoresistant Dystonia

    WK. Lim, ZX. Ching, WHM. Wan Zainuddin, L. Li, CY. Fong, KA. Muthusamy (Kuala Lumpur, Malaysia)

    Objective: To evaluate the clinical outcomes of deep brain stimulation (DBS) in Malaysian children with pharmacoresistant dystonia. Background: Dystonia is a common paediatric movement disorder…
  • 2026 International Congress

    Postural Stability After CSF Drainage in Idiopathic Normal Pressure Hydrocephalus: Association with Gait Response

    HJ. Chang, JH. Kim, EJ. Kwon, S. Jeong, E. Oh (Daejeon, Republic of Korea)

    Objective: To examine changes in postural stability after CSF drainage using center of pressure (COP) analysis and their association with gait response in patients with…
  • 2026 International Congress

    Speech And Gait In Newly Diagnosed Parkinson’s Disease: Support For Early Rehabilitation

    T. Yhlen, E. Franzen, M. Söderholm, S. Grigoriou, S. Whitling, B. Lindholm (Malmö, Sweden)

    Objective: To describe the prevalence of self-reported speech difficulties in newly diagnosed Parkinson’s disease (PD) and to explore its associations with dysphagia, hypersalivation (HS) and…
  • 2026 International Congress

    Objective Parkinson’s Diagnosis Using a Novel Accelerometer Assessment and Machine Learning

    L. Jurcaga, E. Amigo, J. Oyaga-Orus, S. Aldea-Campillo, J. Marín-Lahoz, M. Vallejo (Edinburgh, United Kingdom)

    Objective: To evaluate a novel motor assessment using a handheld accelerometer and machine learning to objectively support Parkinson's disease (PD) diagnosis. Background: PD diagnosis is…
  • 2026 International Congress

    Knee Extensor Strength Is Associated with Torque Generation and Mobility in Parkinsonian Disorders

    S. Komatsu, K. Sato, T. Ogawa, S. Hayasaka, K. Hatori, T. Hatano, T. Fujiwara (Urayasu, Japan)

    Objective: To examine associations among knee extensor strength (KES), torque generation during knee extension quantified by the area under the torque–time curve (AUC), and functional…
  • 2026 International Congress

    Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide

    M. Vale, D. Lopes, H. Brigas, J. Holenz (Coronado, Portugal)

    Objective: To review the safety data of opicapone (OPC) after 10 years of worldwide marketing experience. Background: OPC, a third-generation COMT inhibitor, is approved as…
  • 2026 International Congress

    Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study

    S. Wald Grossman, A. Rieckmann, A. Mehta (Deefield, USA)

    Objective: To assess the direct healthcare costs and healthcare resource utilization (HCRU) of MSA in the US commercially insured population. Background: MSA is a rare,…
  • 2026 International Congress

    Baseline characteristics of fallers versus non-fallers in a remote, decentralized study of Parkinson’s disease

    P. Auinger, R. Wilson, C. Roe, A. Ascherio, J. Beck, S. Benvengo, K. Biglan, E. Dorsey, A. Espay, E. Macklin, M. Monje, E. Neto, D. Novak, M. Schwarzschild, S. Sieberts, T. Simuni, C. Tanner, D. Weintraub, R. Schneider (Rochester, USA)

    Objective: To compare the baseline characteristics of fallers versus non-fallers in a remote, decentralized study of Parkinson’s disease (PD) participants. Background: Falls are common in…
  • 2026 International Congress

    Sleep disorder Clustering and Clinical Impact in Multiple System Atrophy

    D. Dong, L. Li, L. Luo, W. Wang (Hangzhou, China)

    Objective: To characterize clustering patterns of sleep disorders in multiple system atrophy (MSA) and evaluate their clinical impact. Background: Sleep disorders are common in MSA.…
  • 2026 International Congress

    First-in-Human Single-Ascending-Dose Trial of ALN-SNCA, an Intrathecally Administered siRNA for Reducing α-synuclein, in Patients with Early-Stage Parkinson’s Disease

    M. Ahmed, M. Effendi, S. Schneider, M. Rosario, M. Magliocca, A. Gorbenko, B. Bugna, L. Farrelly, P. Kremer, R. Postuma, J. Whitton, A. Avbersek, O. Harari (Tarrytown, USA)

    Objective: Development of a Phase 1, First-in-Human (FIH) clinical trial evaluating ALN-SNCA, a novel, intrathecally (IT) delivered small interfering RNA (siRNA) targeting SNCA mRNA to…
  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley